Physician profile
Edgar Sanchez
NPI 1033347810
$2,124.58
in general payments reported to CMS, 2019-2025
10 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,444 · 2020: $101 · 2021: $128 · 2022: $147 · 2023: $23.93 · 2024: $48.03 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $289 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.65 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $1,323.66 | 2019 | |
| Paratek Pharmaceuticals, INC. | $162.05 | 2022-2024 | Nuzyra |
| Viiv Healthcare Company | $147.37 | 2019-2022 | |
| Insmed, INC. | $116.38 | 2021-2025 | Brinsupri |
| Invivyd INC | $111.27 | 2025 | Pemgarda |
| Ferring Pharmaceuticals INC. | $105.42 | 2025 | Rebyota |
| Gilead Sciences, INC. | $100.69 | 2020 | |
| Merck Sharp & Dohme LLC | $23.93 | 2023 | Delstrigo, Dificid, Pifeltro |
| Organogenesis INC. | $18.74 | 2019 | |
| Smith+Nephew, INC. | $15.07 | 2024 | Grafix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.